Tag: Mitraclip

Northwestern Medicine Celebrates 2000th Transcatheter Heart Valve Procedure

Minimally invasive treatment revolutionized cardiac medicine, replacing open-heart surgery for many patients CHICAGO, Aug. 26, 2020 /PRNewswire/ — Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2000th transcatheter heart valve procedure, a milestone innovation that has shifted valve repair and replacement from operating room to catherization lab, dramatically reducing procedural time, recovery […]

New Late-Breaking Data Highlight Impact of Abbott’s Minimally Invasive Structural Heart Therapies

– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]

Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients

– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at prohibitive risk for surgery) to also include patients at moderate […]

New Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves

– New data presented at TCT 2019 on Abbott’s TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints – Abbott’s TriClip tricuspid valve repair system design is based on the company’s market-leading MitraClip™ technology SAN FRANCISCO, Sept. 28, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new […]

First MitraClip™ Procedure Performed Using the All-in-One VersaCross™ Transseptal Solution

TORONTO, Sept. 23, 2019 /PRNewswire/ – Baylis Medical announced today the successful first MitraClip™ procedure performed using the VersaCross™ Transseptal Solution. The VersaCross solution is the world’s first all-in-one left-heart access device featuring an atraumatic RF-tipped pigtail wire. The device is designed to achieve left-heart access with controlled precision, while reducing the […]

Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott’s Leading MitraClip Platform

ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of […]

TRILUMINATE Study Shows Treatment with Abbott’s First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks

PARIS, May 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company’s minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduction of tricuspid regurgitation (TR) symptoms – caused by a leaky tricuspid heart valve […]


ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery. Supported by the results of the landmark COAPT™ Trial, […]

Landmark Study Shows Treatment with Abbott’s MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

SAN DIEGO, Sept. 23, 2018 /PRNewswire/ — Abbott (NYSE :ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark […]

Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves

ABBOTT PARK, Ill., July 12, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation […]